Anticancer drug bortezomib increases interleukin-8 expression in human monocytes

Biochemical and Biophysical Research Communications
Shannon SanacoraIvana Vancurova

Abstract

Bortezomib (BZ) is the first clinically approved proteasome inhibitor that has shown remarkable anticancer activity in patients with hematological malignancies. However, many patients relapse and develop resistance; yet, the molecular mechanisms of BZ resistance are not fully understood. We have recently shown that in solid tumors, BZ unexpectedly increases expression of the pro-inflammatory and pro-angiogenic chemokine interleukin-8 (IL-8), while it inhibits expression of other NFκB-regulated genes. Since monocytes and macrophages are major producers of IL-8, the goal of this study was to test the hypothesis that BZ increases the IL-8 expression in human monocytes and macrophages. Here, we show that BZ dramatically increases the IL-8 expression in lipopolysaccharide (LPS)-stimulated U937 macrophages as well as in unstimulated U937 monocytes and peripheral blood mononuclear cells, while it inhibits expression of IL-6, IL-1 and tumor necrosis factor-α. In addition, our results show that the underlying mechanisms involve p38 mitogen-activated protein kinase, which is required for the BZ-induced IL-8 expression. Together, these data suggest that the BZ-increased IL-8 expression in monocytes and macrophages may represent one of the...Continue Reading

References

Oct 1, 1989·The Journal of Clinical Investigation·M BaggioliniS L Kunkel
Feb 1, 1995·International Journal of Immunopharmacology·M BaggioliniB Moser
Sep 7, 2001·Cytokine & Growth Factor Reviews·K Xie
May 9, 2002·American Journal of Physiology. Renal Physiology·Hongye Li, Edward P Nord
Jan 19, 2005·Cell Cycle·Paul G RichardsonKenneth C Anderson
Sep 20, 2006·Experimental Hematology·Rohit AggarwalG David Roodman
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David J J Waugh, Catherine Wilson
Sep 11, 2009·Leukemia·J J Shah, R Z Orlowski
Feb 19, 2010·Trends in Molecular Medicine·Gwendal Lazennec, Ann Richmond
Dec 7, 2011·Critical Reviews in Immunology·Manuela RossolSunna Hauschildt
Nov 28, 2013·Pharmaceuticals·Laura M CampbellDavid J J Waugh
Aug 5, 2014·Biochimica Et Biophysica Acta·Tzu-Pei Chang, Ivana Vancurova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.